The use of CAR T-cell therapy has transformed outcomes for relapsed or refractory B-cell malignancies, but access to it remains extremely limited in some countries. Cartogene Therapeutics Pvt Ltd. aimed to address this need by in-licensing CGT-19, a CD19 CAR T construct from Vector Biomed Inc.
Forx Therapeutics AG presented a comprehensive preclinical medicinal chemistry and translational profiling program describing the optimization of potent and selective poly(ADP-ribose) glycohydrolase inhibitors, which led to the identification of FORX-428, currently in phase I clinical trials. The company also disclosed the chemical structure of the compound.
As expected, the EMA is recommending withdrawal of the mpox indication for Siga Technologies Inc.’s tecovirimat, whilst maintaining its approval as a treatment for smallpox, cowpox and adverse reactions to vaccinia vaccines.
Chengdu Sibeibo Pharmaceutical Technology Co. Ltd. has reported new poly(ADP-ribose) polymerase 14 (PARP-14; ARTD8) inhibitors potentially useful for the treatment of cancer, asthma, atopic dermatitis and infectious pneumonia.
Previously, Chinese researchers used long-read RNA sequencing to identify a unique alternative splicing variant of CD44 transmembrane protein, named CD44E, which is highly expressed in hepatocellular carcinoma (HCC) tumors compared to adjacent nontumoral liver tissues. In a new study, the team analyzed the Genotype-Tissue Expression (GTEx) database and confirmed that CD44E expression is limited in essential normal organs, while CD44S standard isoform is broadly expressed on most cell types.
Onkure Therapeutics Inc. has announced an oversubscribed $150 million private placement which the company intends to use to fund the preclinical and clinical development of its next-generation PI3Kα pan-mutant selective inhibitor candidates in breast cancer and vascular anomalies.
IKZF1-4 are transcription factors that regulate cellular differentiation, proliferation and survival. At the American Chemical Society (ACS) Spring 2026 meeting this week in Atlanta, Bristol Myers Squibb Co. detailed the identification and preclinical profile of BMS-986482, a next-generation investigational cereblon E3 ligase modulator (CELMoD) degrader designed to target IKZF1-4 factors.
Multispecifics took center stage at this year’s ESMO TAT, emerging as one of the hottest trends in oncology research. Unlike traditional small-molecule drugs or monoclonal antibodies that typically target a single protein, multispecific compounds are engineered to harness multiple mechanisms of action within a single molecule. They orchestrate biology rather than just blocking it.
In a small Houston clinic, more than a decade ago, patients with advanced cancer were receiving treatments that used radioactive molecules to seek out tumors and destroy them from within using an approach that would eventually help reshape oncology.
RSS
